Top U.S. Contraceptive Companies

U.S. Contraceptive Market size was valued at USD 9 Billion in 2024 and is poised to grow from USD 9.43 Billion in 2025 to USD 13.61 Billion by 2033, growing at a CAGR of 4.7% during the forecast period (2026–2033).

The U.S. contraceptive market is highly competitive, with a diverse range of products and key players. The market is primarily driven by the growing awareness of reproductive health and increasing adoption of long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and implants. Prominent players like Bayer AG, Johnson & Johnson, and Pfizer dominate with a strong product portfolio that includes oral contraceptives, condoms, and hormonal devices. The market also sees rising competition from newer entrants offering innovative products like non-hormonal contraceptives, emergency contraceptive pills, and male contraceptives, gaining traction due to shifting consumer preferences for alternatives. Additionally, strategic collaborations and product launches, such as Bayer's IUD advancements and innovative contraceptive pills by HRA Pharma, further intensify competition. The regulatory landscape, evolving consumer demands, and ongoing investments in R&D are expected to shape the competitive dynamics, with companies focusing on accessibility, affordability, and sustainability. 'Pfizer Inc. (United States)', 'Merck & Co., Inc. (United States) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Bayer AG (Germany) ', 'Organon & Co. (United States) ', 'Agile Therapeutics, Inc. (United States) ', 'TherapeuticsMD, Inc. (United States) ', 'Mithra Pharmaceuticals (Belgium) ', 'Reckitt Benckiser Group plc (United Kingdom) ', 'Church & Dwight Co., Inc. (United States) ', 'The Cooper Companies, Inc. (United States) ', 'AbbVie Inc. (United States) ', 'Viatris Inc. (United States) ', 'Amneal Pharmaceuticals, Inc. (United States) ', 'Afaxys, Inc. (United States)'

The high prevalence of STIs within the U.S. is a primary driver in the contraceptive market, as it has been estimated to be over 2.4 million reported cases in 2023. With such growing concern among sexually active individuals, there is an increased demand for dual-protection methods. Public health campaigns and the 2024 STI Prevention Conference, with over 1,200 attendees and 251 poster presentations, indicate that the need for using contraceptives has increased for preventing pregnancyand STIs. Condoms have become the favorite barrier method that is fueling market growth.

Rising consumer demand for safer, natural contraceptive options: A meteoric increase in research and investment in non-hormonal contraceptives was spurred by high consumer demand for alternatives to hormonal contraceptives, coupled with the increasingly alarming side effects and health risks associated with hormonal birth control. Active efforts are being made to develop and test non-hormonal methods such as copper IUDs, fertility awareness-based methods, and barrier options like condoms and diaphragms. This will have a major impact on the future growth of the non-hormonal contraceptive market, as this demand is from safer and more natural alternatives. According to the Guttmacher Institute, 30% of women are interested in non-hormonal methods due to hormonal birth control side effects and health risks, which was reported by a 2021 survey. The increasing interest in non-hormonal contraceptives reflects a growing consumer awareness of the long-term effects of hormonal methods and a larger market shift toward holistic wellness.

U.S. contraceptive market is experiencing steady growth, driven by increasing awareness of reproductive health and the availability of advanced contraceptive options. Our study reveals that the market is segmented into hormonal and non-hormonal methods, with hormonal contraceptives, including oral pills, implants, and IUDs, holding the largest share. The rising preference for long-acting reversible contraceptives (LARCs) is a key trend, as they offer convenience and higher efficacy rates.